pg545
Small moleculeexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2011 (NCT01252095)
Timeline
Indications
Mechanism of action
- HeparanaseINHIBITOR
HPSE inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@@H](O[C@@H]5O[C@H](COS(=O)(=O)O)[C@@H](O[C@H]6O[C@H](COS(=O)(=O)O)[C@@H](O[C@H]7O[C@H](COS(=O)(=O)O)[C@@H](O[C@H]8O[C@H](COS(=O)(=O)O)[C@@H](OS(=O)(=O)O)[C@H](OS(=O)(=O)O)[C@H]8OS(=O)(=O)O)[C@H](OS(=O)(=O)O)[C@H]7OS(=O)(=O)O)[C@H](OS(=O)(=O)O)[C@H]6OS(=O)(=O)O)[C@H](OS(=O)(=O)O)[C@H]5OS(=O)(=O)O)CC[C@]4(C)[C@H]3CC[C@]12C- Mol. weight
- 2078.08 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2078841 ↗
Also known as
- pg545
- pg545
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05061017 | Phase 2 | Oct 28, 2021 | University of Pittsburgh, Zucero Pty Ltd |
| NCT02042781 | Phase 1 | Jan 1, 2014 | Progen Pharmaceuticals, University of Western Australia |
| NCT01252095 | Phase 1 | Jan 1, 2011 | Datapharm Australia Pty Ltd, Progen Pharmaceuticals, Statistical Revelations Pty Ltd, University of Western Australia |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Progen Pharmaceuticals | For profit | 2 | 2 | 1 | 2011 |
| University of Western Australia | Academic/Hospital | 2 | 0 | 1 | 2011 |
| Datapharm Australia Pty Ltd | For profit | 1 | 0 | 1 | 2011 |
| Statistical Revelations Pty Ltd | For profit | 1 | 0 | 1 | 2011 |
| University of Pittsburgh | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Zucero Pty Ltd | For profit | 1 | 0 | 1 | 2021 |
6 organizations
Page 1 / 1